ETORICOXIB VERSUS PIROXICAM IN ACCENTUATING THE COGNITIVE FUNCTIONS
Keywords:
Etoricoxib, choice reaction time, critical flicker fusion, piroxicamAbstract
Cognitive functions are processes of knowing. When it is impaired, reviving is needed. Studies to bustle off the psychomotor activities using COX-1 inhibitors revealed variable results. Aim: To evaluate the effects of a single oral dose of etoricoxib and piroxicam (COX-2 inhibitors) on cognitive activity in healthy, young volunteers. Subjects and Methods: Thirty-two healthy young volunteers were participated, allocated into two groups. After a7-day washed-out period, each participant was randomly given a single oral dose of either etoricoxib (90mg) or piroxicam (10mg) or placebo. Psychomotor tests were performed to record their sensory and motor reactions. Results: the placebo-administered subjects had non-significant changes in both choice reaction time and critical flicker fusion. Etoricoxib-administered subjects had a significantly reduced recognition reaction time without a significant effect on motor reaction time. While piroxicam-administered ones had a significant reduction in motor reaction time without a significant effect on recognition reaction time. All drug-given individuals had a non-significant change in choice reaction time when compared with corresponding baseline and placebo values.
References
Von Eckardt B. What is cognitive science?. Princeton, MA: MIT Press. 1996; pp. 45–72
Franchi S, Bianchini F. On The Historical Dynamics Of Cognitive Science: A View From The Periphery. The Search for a Theory of Cognition: Early Mechanisms and New Ideas. Amsterdam: Rodopi. 2011; p. 15
Baker PM, Jhou T, Li B, Matsumoto M, Mizumori SJ, Stephenson-Jones M, Vicentic A. The Lateral Habenula Circuitry: Reward Processing and Cognitive Control. J Neurosci. 2016 ;36(45):11482-8.
Allison Gartung, Jiawei Zhao, Simon Chen, Emilio Mottillo, Garrett VanHecke. Characterization of Eicosanoids Produced by Adipocyte Lipolysis: IMPLICATION OF CYCLOOXYGENASE-2 IN ADIPOSE INFLAMMATION. J. Biol. Chem. 2016; 291: 16001-3
Liang Dong, Chong Yuan, Benjamin J. Fatty Acid Binding to the Allosteric Subunit of Cyclooxygenase-2 Relieves a Tonic Inhibition of the Catalytic Subunit. J. Biol. Chem. 2016; 291: 25641-4.
Frampton JE, Keating GM. Etoricoxib: a review of its use in the management of acute pain. Drugs 2007; 67(16):2433-72.
Guangming Liu, Wei-Ya Ma, Ann M. Bode, Yiguo Zhang, Zigang Dong. Piroxicam Suppress UVB-induced Activator Protein 1 Activity by Mechanisms Independent of Cyclooxygenase-2. J. Biol. Chem. 2003; 278: 2124-8.
Bickham K, Kivitz AJ, Mehta A, Frontera N, Shah S, Stryszak P, Popmihajlov Z, Peloso PM. Evaluation of two doses of etoricoxib, a COX-2 selective non-steroidal anti-inflammatory drug (NSAID), in the treatment of Rheumatoid Arthritis in a double-blind, randomized controlled trial. BMC Musculoskelet Disord. 2016 8; 17:331.
Zolotovskaya, I. L. Davydkin. the Cognitive Cytokine Effect of Nonsteroidal Antiinflammatory Drugs in the Treatment of Elderly Patients with Osteoarthritis. Advances in Gerontology. 2018; volume 8, page 26–32.
Parkin C, Kerr JS, Hindmarch I. The effects of practice on choice reaction time and critical flicker fusion threshold. Hum Psy Clin Exp 1999; 12:65-70.
Hindmarch I. Psychomotor function and psychoactive drugs. Br J Clin Pharmacol 1980; 10: 189-209.
Ravnkilde B, Videbech P, Rosenbergt R, et al. Putative tests of frontal lobe function: neuropsychological tests during Stroop’s test and verbal fluency. J Clin Exp Neuropsychol. 2002; 24:534–47.
Xue Y.-H., Peng Y.-S., Ting H.-F., Peijer Hsieh J.et al. Etoricoxib and Diclofenac Might Reduce the Risk of Dementia in Patients with Osteoarthritis: A Nation-Wide, Population-Based Retrospective Cohort Study.Dement Geriatr Cogn Disord 2018;45:262–271
Gary W. Small, Prabha Siddarth, Daniel HS. Silverman, et al. Cognitive and Cerebral Metabolic Effects of Celecoxib Versus Placebo in People With Age-Related Memory Loss: Randomized Controlled Study. Am J Geriatr Psychiatry. 2008; 16(12): 999–1009.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
